MCHI vs XBI
iShares MSCI China ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.59% for MCHI.
- • MCHI pays a higher dividend yield (2.24%).
Side-by-side metrics
| Metric | MCHI | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.59% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.24% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $5.49B | $10.92B |
YTD return | -13.67% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.47 | 1.01 |
P/E ratio | 11.44 | — |
Last price | $50.65 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
MCHI top holdings
| 0700.HK | Tencent Holdings Ltd | 13.21% |
| 9988.HK | Alibaba Group Holding Ltd Ordinary Shares | 9.14% |
| 00939 | China Construction Bank Corp Class H | 4.84% |
| 01398 | Industrial And Commercial Bank Of China Ltd Class H | 2.88% |
| 1810.HK | Xiaomi Corp Class B | 2.54% |
| 03988 | Bank Of China Ltd Class H | 2.30% |
| 3690.HK | Meituan Class B | 2.02% |
| PDD | PDD Holdings Inc ADR | 1.78% |
| 9999.HK | NetEase Inc Ordinary Shares | 1.75% |
| 02318 | Ping An Insurance (Group) Co. of China Ltd Class H | 1.72% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About MCHI
MCHI (iShares MSCI China ETF) is Broad China equity exposure. Managed by iShares, the fund carries $5.5B in assets under management, an expense ratio of 0.59%, a dividend yield of 2.24%. Its largest holding is Tencent Holdings Ltd (0700.HK), which represents 13.2% of the portfolio. Real Estate is the fund's largest sector exposure at 1.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.